心血管病防治知识（下半月）
心血管病防治知識（下半月）
심혈관병방치지식（하반월）
XINXUEGUANBING FANGZHI ZHISHI
2014年
12期
75-77
,共3页
重症%慢性心力衰竭%个体化%药物治疗
重癥%慢性心力衰竭%箇體化%藥物治療
중증%만성심력쇠갈%개체화%약물치료
Severe%Chronic heart failure%Personalized%Medication
目的：探讨重症慢性心力衰竭患者的个体化药物治疗效果。方法随机选取2013年1月-2014年1月来我院就诊的重症慢性心力衰竭患者50例。根据患者的个体情况，对患者给予不同种类和剂量的利尿剂、血管扩张剂、醛固醇类、血管紧张素Ⅱ受体拮抗剂等药物的治疗。对患者在治疗前后治疗的显效、有效、无效情况进行分析；记录患者在住院第一周、第二周、第三周和第四周的入院住院费用，并计算人均日住院费用；对患者在治疗前后的心率值、收缩压、舒张压、LVEF、LVDD等情况进行分析。结果患者治疗后显效例数为35例，有效例数为14例，无效例数为1例，总的治疗有效率达到98%；患者在治疗后，心率、收缩压、舒张压、LVDD、LVEF等指标都有了显著的改善，差异显著，P<0.05；患者在住院第一周花费的费用最大，并且随着病情的逐渐好转，患者花费的住院费用逐渐下降，差异显著，P<0.05；人均日住院费用随着治疗时间的增加逐渐下降，差异显著，P<0.05。结论重症慢性心力衰竭患者在治疗时，应该进行个体化药物治疗，以最大程度地较少患者的治疗费用，并达到最好的治疗效果。
目的：探討重癥慢性心力衰竭患者的箇體化藥物治療效果。方法隨機選取2013年1月-2014年1月來我院就診的重癥慢性心力衰竭患者50例。根據患者的箇體情況，對患者給予不同種類和劑量的利尿劑、血管擴張劑、醛固醇類、血管緊張素Ⅱ受體拮抗劑等藥物的治療。對患者在治療前後治療的顯效、有效、無效情況進行分析；記錄患者在住院第一週、第二週、第三週和第四週的入院住院費用，併計算人均日住院費用；對患者在治療前後的心率值、收縮壓、舒張壓、LVEF、LVDD等情況進行分析。結果患者治療後顯效例數為35例，有效例數為14例，無效例數為1例，總的治療有效率達到98%；患者在治療後，心率、收縮壓、舒張壓、LVDD、LVEF等指標都有瞭顯著的改善，差異顯著，P<0.05；患者在住院第一週花費的費用最大，併且隨著病情的逐漸好轉，患者花費的住院費用逐漸下降，差異顯著，P<0.05；人均日住院費用隨著治療時間的增加逐漸下降，差異顯著，P<0.05。結論重癥慢性心力衰竭患者在治療時，應該進行箇體化藥物治療，以最大程度地較少患者的治療費用，併達到最好的治療效果。
목적：탐토중증만성심력쇠갈환자적개체화약물치료효과。방법수궤선취2013년1월-2014년1월래아원취진적중증만성심력쇠갈환자50례。근거환자적개체정황，대환자급여불동충류화제량적이뇨제、혈관확장제、철고순류、혈관긴장소Ⅱ수체길항제등약물적치료。대환자재치료전후치료적현효、유효、무효정황진행분석；기록환자재주원제일주、제이주、제삼주화제사주적입원주원비용，병계산인균일주원비용；대환자재치료전후적심솔치、수축압、서장압、LVEF、LVDD등정황진행분석。결과환자치료후현효례수위35례，유효례수위14례，무효례수위1례，총적치료유효솔체도98%；환자재치료후，심솔、수축압、서장압、LVDD、LVEF등지표도유료현저적개선，차이현저，P<0.05；환자재주원제일주화비적비용최대，병차수착병정적축점호전，환자화비적주원비용축점하강，차이현저，P<0.05；인균일주원비용수착치료시간적증가축점하강，차이현저，P<0.05。결론중증만성심력쇠갈환자재치료시，응해진행개체화약물치료，이최대정도지교소환자적치료비용，병체도최호적치료효과。
Objective To investigate efficacy of personalized medication for severe chronic heart failure. Methods Fifty patients with severe chronic heart failure who were admitted to our hospital from January 2013 to January 2014 were randomly collected and evaluated. Patients were treated with different types and doses of diuretics, vasodilators, aldehyde steroids, or angiotensin II receptor antagonists, based on individual patient data. The numbers of patients with marked response, response, and no response after treatment were evaluated. Inpatient costs at weeks 1, 2, 3, and 4 of treatment were recorded and the mean cost per inpatient day were calculated. Heart rate, systolic pressure, diastolic pressure, left ventricular ejection fraction (LVEF), and left ventricular end-diastolic dimension (LVDd) were evaluated before and after treatment. Results After treatment, the numbers of patients with marked response, response, and no response were 35, 14, and 1, respectively, which resulted in an overall response rate of 98%. The heart rate, systolic pressure, diastolic pressure, LVEF, and LVDd were significantly improved after treatment (P<0.05). The inpatient cost was the highest at the first week of treatment and significantly decreased along with recovery of patients (P<0.05). The mean cost per inpatient day showed a significant time-dependent decrease during the course of treatment (P<0.05). Conclusion Patients with severe chronic heart failure should be treated with personalized medication to achieve the best clinical outcomes with the lowest inpatient cost.
